前列腺癌体系突变及治疗研究进展  

Research Progress of Prostate Cancer Somatic Mutation and Treatment

作　　者：吴礼益 严维刚[1] WU Liyi;YAN Weigang(Department of Urology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China)

机构地区：[1]中国医学科学院北京协和医院泌尿外科,北京100730

出　　处：《协和医学杂志》2023年第4期839-843,共5页Medical Journal of Peking Union Medical College Hospital

基　　金：中央高水平医院临床科研专项(2022-PUMCH-A-063)。

摘　　要：前列腺癌是目前全球最常见的男性恶性肿瘤之一,严重威胁中老年男性健康。前列腺癌患者的临床表现和疾病预后具有个体差异,低危患者病程缓慢,死亡风险较低,而中高危患者预后较差,死亡风险较高。目前研究表明,前列腺癌的临床表现与基因突变相关,而体系突变作为前列腺癌基因突变的重要组成部分,与肿瘤的发生转移相关,可作为前列腺癌患者危险分级预后预测的潜在依据。本文就前列腺癌体系突变及治疗研究进展作一综述,以期为该疾病的诊断治疗提供借鉴。Prostate cancer,one of the most common male malignancies in the world,seriously threatens the health of middle⁃aged and elderly men.The clinical manifestations and prognosis of prostate cancer patients have individual differences.Most low⁃risk patients have a slow disease course and a low risk of death,while inter⁃mediate⁃and high⁃risk patients have a poor prognosis and a high risk of death.Current studies have shown that prostate cancer genes have complex genetic heterogeneity associated with clinical manifestations and somatic muta⁃tion is an important part of prostate cancer genome variations.With the development of high⁃throughput sequencing technology,related research is increasing.This article reviews the research progress on somatic muta⁃tions in prostate cancer and treatment to provide reference for prognosis prediction and drug treatment of the disease.

关 键 词：前列腺癌 体系突变 研究进展 诊疗价值 

分 类 号：R737.25[医药卫生—肿瘤] Q344.12[医药卫生—临床医学]